Development of Vitreous Haemorrhage during Treatment with Bevacizumab for Metastatic Rectal Cancer

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.28, Iss.8, 2008-01, pp. : 523-526

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab: In First-Line Treatment of Metastatic Breast Cancer

By Scott Lesley J.

Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. : 1793-1799

Adis International

Access to resources Recommend Favorite

Bevacizumab in First-Line Treatment of Metastatic Breast Cancer: A Viewpoint by David Miles

By Miles David

Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. : 1800-1801

Adis International

Access to resources Recommend Favorite

Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer

By > Pietrantonio Filippo Martinetti Antonia Buzzoni Roberto Gevorgyan Arpine Bajetta Emilio

Drugs & Aging, Vol. 28, Iss. 2, 2011-02 ,pp. : 83-91

Adis International

Access to resources Recommend Favorite

Use of Bevacizumab in Metastatic Colorectal Cancer: Report from the Mexican Opinion and Analysis Forum on Colorectal Cancer Treatment with Bevacizumab (September 2009)

By Zinser-Sierra Juan W.

Drugs in R&D, Vol. 11, Iss. 2, 2011-06 ,pp. : 101-111

Adis International

Access to resources Recommend Favorite

Bevacizumab [Avastin; Roche] has been launched in the UK as a first-line treatment for metastatic breast cancer

Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite